ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.65
0.48%
US Tech 100
18,318.00
0.95%
S&P 500
5,304.72
0.70%
US Dollar vs CAD
1.36589
-0.07%
Bitcoin
68,567.55
0.08%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Keros Therapeutics Inc (KROS)

  7. Keros Therapeutics Inc (KROS) News

KROS

Keros Therapeutics (KROS)

Keros Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KROS
DateTimeSourceHeadlineSymbolCompany
05/14/20249:00AMGlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
05/08/20247:03AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
05/08/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
05/08/20247:00AMGlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
03/14/20247:00AMGlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
03/06/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/05/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/05/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/05/20247:00AMGlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
02/28/20243:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
02/28/20243:01PMGlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
02/23/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
02/15/20247:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
02/15/20247:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
02/15/20247:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
02/15/20247:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
01/29/20247:00AMGlobeNewswire Inc.Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual CongressNASDAQ:KROSKeros Therapeutics Inc
01/09/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
01/09/20247:00AMGlobeNewswire Inc.Keros Therapeutics Announces Closing of Upsized Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
01/08/20243:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
01/04/20243:04PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
01/04/20243:04PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KROSKeros Therapeutics Inc
01/04/20243:02PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KROSKeros Therapeutics Inc
01/03/20248:29PMGlobeNewswire Inc.Keros Therapeutics Announces Pricing of Upsized Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
01/03/20243:05PMGlobeNewswire Inc.Keros Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:KROSKeros Therapeutics Inc
01/03/20243:04PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:KROSKeros Therapeutics Inc
01/03/20247:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
12/11/20235:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
12/11/20235:00AMGlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and ExpositionNASDAQ:KROSKeros Therapeutics Inc
11/07/20237:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KROS

Your Recent History

LSE
SONC
Hipgnosis Songs
KOSPI
005610
SPC Samlip
BIT
F15248
Vontobel Financial Produ...
BIBX
HOTUSDT
HoloToken
BIT
F18146
Vontobel Financial Produ...
BOV
L1EG34
Leggett Platt
BIT
F12475
Vontobel Financial Produ...
EU
P789S
P789S
NASDAQ
FWSBCX
Strategic International ...
NYSE
PGRU
PropertyGuru
NYSE
HIW
Highwoods Properties
NYSE
PRE-I
PartnerRe
NYSE
CNDA
Concord Acquisition Corp...
COIN
TKXETH
Tokenize Xchange Emblem
DGFX
RETUSDT
Renewable Energy Token
BIT
FLV025
Vontobel
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved